The information in the below press release is intended for investors.

Archive for April, 2021

  • Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

    GOTHENBURG, Sweden, April 28, 2021 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), hereby announces that…

  • Interviewed made by Redeye

    Redeye has interviewed Ulf Jungnelius, CEO of Isofol, regarding the announcement that the AGENT study will be completed with 440…